Case Western Reserve University, Tracon deal

The partners added more patents to a 2006 deal granting Tracon rights to certain patents, know-how and IP regarding methoxyamine ( TRC102). The addition includes patent applications covering combinations of methoxyamine with approved chemotherapeutic agents and the use of predictive treatment biomarkers. Methoxyamine is a small molecule inhibitor of the DNA base-excision repair pathway that reverses chemotherapy resistance in patients with lung cancer, brain cancer and other malignancies. Case remains eligible for the same total of development and regulatory milestones. Case is also eligible for royalties. ...